✨ Free AI Report
Astellas Gene Therapies, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Astellas Gene Therapies, Inc.
Research Preview

Astellas Gene Therapies, Inc.: Business Overview, Financials & Competitive Analysis

Astellas Gene Therapies is a developer of gene therapies for the treatment of rare diseases. The company aims to become a global leader in genetic medicines using adeno-associated viruses (AAVs) to introduce correctiv...

Analyst-debate audio for Astellas Gene Therapies, Inc.

AskCyborg analysts argue the bull and bear cases for Astellas Gene Therapies, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Astellas Gene Therapies, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Private biotech subsidiary with differentiated AAV gene therapy platform and manufacturing scale positioning for potential rare...

Read the full analyst-debate transcript →
Industry Gene Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Astellas Gene Therapies, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Astellas Gene Therapies, Inc. Overview

Pro stress-test →

Astellas Gene Therapies is a developer of gene therapies for the treatment of rare diseases. The company aims to become a global leader in genetic medicines using adeno-associated viruses (AAVs) to introduce corrective genes into cells that have faulty or missing genes. The company has invested $100 million in a biomanufacturing facility in Sanford, North Carolina with the promise of creating more than 200 jobs through 2026.

Strategic Profile

Pro stress-test →

Astellas Gene Therapies is exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown for targeted therapies. As of January 2026, instead of developing the AAV-based resamirigene bilparvovec (AT132) on its own, Astellas is partnering with Kate Therapeutics—acquired in 2024 by Novartis for up to $1.1 billion—to develop a MyoAAV capsid-based gene therapy for XLMTM.

Competitive Landscape

Pro stress-test →

Top competitors include Alnylam, BridgeBio and Spark Therapeutics. The gene therapy landscape for rare diseases is increasingly competitive, with multiple AAV and non-AAV platforms advancing. Astellas' differentiation lies in its MyoAAV capsid partnership and manufacturing scale, though larger biotech and pharma players maintain broader resources and pipeline depth.

Industry Context

Astellas Gene Therapies, Inc. operates in Gene Therapy.

Key facts

Founded: 2012 · Headquarters: San Francisco, US · Employees: 777 · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Astellas Gene Therapies, Inc..

+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Astellas Gene Therapies, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Onpattro (patisiran)RNAi therapeutics for rare genetic diseases including hereditary transthyretin amyloidosis→Gene therapy platformGene therapies and genomic medicines for rare genetic diseases→Luxturna (voretigene neparvovec)AAV gene therapy for inherited retinal dystrophies and other rare diseases→

Compare Astellas Gene Therapies, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Astellas Gene Therapies, Inc. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Astellas Gene Therapies, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Astellas Gene Therapies, Inc. and its top competitor on Cyborg Score”
“What did Astellas Gene Therapies, Inc. do this quarter?”
“Is Astellas Gene Therapies, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Astellas Gene Therapies, Inc. do?+
Astellas Gene Therapies is a developer of gene therapies for the treatment of rare diseases. The company aims to become a global leader in genetic medicines using adeno-associated viruses (AAVs) to introduce correctiv...
What is Astellas Gene Therapies, Inc.'s Cyborg Score?+
Astellas Gene Therapies, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Astellas Gene Therapies, Inc.'s main competitors?+
Named competitors include Onpattro (patisiran), Gene therapy platform, Luxturna (voretigene neparvovec). The full competitive landscape is in the AskCyborg report.
How can I get the full Astellas Gene Therapies, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Astellas Gene Therapies, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Astellas Gene Therapies, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.